Skip to main content

Table 3 Outcomes in selenium and control groups

From: Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial

Outcomes Selenium supplementation group Controls p value
Primary outcome
 Composite endpoints 36 (78.3%) 43 (79.6%) 0.867
  All-cause deaths 3 (6.5%) 9 (16.7%) 0.137
  NYHA II to IV 18 (39.1%) 37 (68.5%) 0.006*
  LVEF< 55.0% 33 (71.7%) 38 (70.4%) 0.944
Secondary outcome
 Rehospitalisatons 4 (8.7%) 8 (14.8%) 0.533
  1. NYHA, New York Heart Association; LVEF, LV ejection fraction; *, p value statistically significant. All values were expressed as mean ± standard deviation, or as proportions